• OPEN AN ACCOUNT
Indian Indices
Nifty
25,461.30 0.30
(0.00%)
Sensex
83,442.50 9.61
( 0.01%)
Bank Nifty
56,949.20 -82.70
( -0.15%)
Nifty IT
38,866.95 -299.60
( -0.76%)
Global Indices
Nasdaq
44,849.54 344.11
(0.77%)
Dow Jones
6,300.35 51.93
(0.83%)
Hang Seng
39,585.13 -225.75
(-0.57%)
Nikkei 225
8,806.53 -16.38
(-0.19%)
Forex
USD-INR
85.44 -0.20
(-0.23%)
EUR-INR
100.61 -0.32
(-0.32%)
GBP-INR
116.59 -0.52
(-0.45%)
JPY-INR
0.59 0.00
(-0.64%)

EQUITY - MARKET SCREENER

Ajooni Biotech Ltd
Industry :  Food - Processing - Indian
BSE Code
ISIN Demat
Book Value()
535040
INE820Y01021
5.1136135
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJOONI
29.3
100.93
EPS(TTM)
Face Value()
Div & Yield %
0.2
2
0
 

Wanbury's Patalganga facility receives GMP certification from ANVISA
May 20,2025
Earlier this month, on 12 May 2025, the company had also received GMP approval from ANVISA for its Tanuku site in Andhra Pradesh.

The certification for the Patalganga site follows ANVISA’s review of the inspection report of U.S. FDA, along with other documents submitted by the company. Based on the evaluation, ANVISA granted the GMP certification, confirming the facility’s compliance with Brazilian regulatory standards.

With this certificate, now both the API manufacturing sites of Wanbury continue to be compliant per ANVISA' s rules & regulations.

Wanbury is a pharmaceutical company with a presence in the global API market and domestic branded formulations.

The company's consolidated net profit declined 88.12% to Rs 1.22 crore as revenues fell by 8.28% to Rs 133.45 crore in Q3 FY25 as compared with Q3 FY24.

The counter declined 1.74% to Rs 299.35 on the BSE.